We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience.
- Authors
LOGOTHETIS, CONSTANTINE N.; HORVAT, NATHAN P.; KURIAN, TONY; BELLO, CELESTE; ISENALUMHE, JULIO LEIDY; SHAH, BIJAL; SOKOL, LUBOMIR; SAEED, HAYDER; PINILLA, JAVIER; GABALLA, SAMEH
- Abstract
Extranodal marginal zone lymphoma (EMZL) encompasses 70% of cases of marginal zone lymphoma. Frontline bendamustine and rituximab (BR) were derived from trials involving other indolent non-Hodgkin's lymphomas. Only one trial has evaluated frontline BR prospectively in EMZL. This retrospective study reports outcomes among EMZL patients receiving frontline BR. Twenty-five patients were included with a median age of 69 years (40--81). Five (20.0%) patients had stage I/II disease, and 20 (80.0%) had stage III/IV disease. The median number of cycles was 6.0 (3.0--6.0). Maintenance rituximab was administered to 10 (41.7%) individuals. Overall response rate (ORR) was 100.0% (60.0% complete response, 40.0% partial response). Medians of overall survival and progression-free survival were not reached. The estimated 2-year progression-free survival was 85.2% and overall survival was 100.0%. Four (16.6%) patients had infections related to treatment; 3 (12.0%) transformed to diffuse large B-cell lymphoma; 5 (20.8%) had a relapse or progression of EMZL; and 3 (12.0%) died unrelated to BR. BR is an efficacious and well-tolerated front-line regimen for EMZL with response data consistent with existing literature.
- Subjects
MUCOSA-associated lymphoid tissue lymphoma; PROGRESSION-free survival; RITUXIMAB; DIFFUSE large B-cell lymphomas; OVERALL survival; SURVIVAL rate
- Publication
Oncology Research, 2024, Vol 32, Issue 6, p1031
- ISSN
0965-0407
- Publication type
Article
- DOI
10.32604/or.2024.046885